Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977756 · ClinicalTrials.gov registry record
IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
A clinical trial, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Completed
- Registry status
- 168
- Enrollment target
NCT00977756 is a clinical trial that has completed, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 168 participants.
The verdict
NCT00977756 has completed, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- COMPLETED
- Registry status
- 168 participants
- Enrollment target
Study Summary
This study will examine drug and body interactions in children receiving anti-HIV treatment regimens using new medications. Drug regimens to be examined will feature the medications raltegravir (RAL), maraviroc (MVC), and etravirine (ETV). These drugs will not be provided through the study.
Interventions
- DRUG Raltegravir (RAL)
- DRUG Atazanavir (ATV)
- DRUG Ritonavir (RTV)
- DRUG Tenofovir (TDF)
- DRUG Etravirine (ETV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2002-08 |
| Est. Completion | 2014-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977756
The ClinicalTrials.gov registry entry for NCT00977756 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Raltegravir (RAL) is the first listed.
NCT00977756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00977756 about?
NCT00977756 is a clinical study titled "IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults". This study will examine drug and body interactions in children receiving anti-HIV treatment regimens using new medications. Drug regimens to be examined will feature the medications raltegravir (RAL), maraviroc (MVC), and etravirine (ETV). These drugs will not be provided through the study.
What is the current status of trial NCT00977756?
This trial is currently completed. The enrollment target is 168 participants. The study started on 2002-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00977756?
The interventions under investigation include: Raltegravir (RAL) (DRUG), Atazanavir (ATV) (DRUG), Ritonavir (RTV) (DRUG), Tenofovir (TDF) (DRUG), Etravirine (ETV) (DRUG).
Who is sponsoring clinical trial NCT00977756?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.